The next meaningful headline may come out of the meeting being held on Sept 4, 2014.
With Aid Doctors Gone, Ebola Fight Grows Harder
"Dr. Kieny has begun cataloging available doses of experimental drugs and vaccines in preparation for a Sept. 4 meeting on their possible use and testing in the outbreak."
I'd hate to be short if Tekmira's TKM-ebola ends up on that list of experimental treatments to be tried. And, odds are high it will be tried since the animal studies did well.
The TKMR pipeline includes several other things of interest. The Ebola scare has brought new eyes to this.
"Within our TKM-PLK1 clinical trial targeting GI-NET and ACC patients, we saw an additional RECIST qualifying Partial Response (PR), defined as a greater than 30 percent reduction in target tumor lesions. This patient is continuing on therapy and has achieved a 44 percent reduction in their target tumor mass, located outside of the liver. Furthermore, scans of the target tumor lesions demonstrate signs of necrosis, indicative of anti-tumor activity.
• We have initiated a Phase I/II clinical study of TKM-PLK1 in patients with Hepatocellular Carcinoma (NYSE:HCC).
• We intend to file an Investigational New Drug (NYSE:IND) application, or equivalent, in the second half of 2014, in order to advance our TKM-HBV program into a Phase I clinical study, with initial data available in 2015. "
Long or short, it's a high risk play if you aren't in for a long term investment. Trading is very volatile now.
Disclosure: The author is long TKMR.